Innovent Biologics, Inc. develops, manufactures and commercializes biopharmaceutical medicines for oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas. News from Innovent centers on product approvals and commercial updates in China, clinical and preclinical data for pipeline assets, medical-congress presentations, and partner-reported development updates. Recurring drug and program references include mazdutide for type 2 diabetes, IBI363 in cancer immunotherapy, IBI324/OLN324 for retinal disease, tigulixostat/IBI128 for gout, and immunology assets such as picankibart/IBI112, IBI3013 and IAR129.
Innovent Biologics has achieved a significant milestone with the first patient dosing of IBI3020, a groundbreaking dual-payload CEACAM5 ADC, in a Phase 1 clinical trial for advanced solid tumors. This marks a global first-in-class development in cancer treatment technology.
The multi-regional Phase 1 study, approved in both China and the U.S., will evaluate the safety, tolerability, and preliminary efficacy of IBI3020. The drug, developed from Innovent's proprietary DuetTx® dual-payload ADC platform, works by selectively binding to CEACAM5-expressing tumor cells and releasing two types of cytotoxic payloads to kill cancer cells.
Preclinical studies have shown promising results, with IBI3020 demonstrating strong antitumor activity and manageable safety profiles. The drug targets CEACAM5, a protein overexpressed in various solid tumors including colorectal cancer, non-squamous lung cancer, gastric cancer, and pancreatic cancer, while showing limited expression in healthy tissues.
Innovent Biologics (HKEX: 01801) presented preclinical data for multiple novel cancer treatments at the AACR Annual Meeting 2025 in Chicago. The presentations showcased several groundbreaking developments including:
- IAR037: A novel CD40/PD-L1 bispecific antibody for treating advanced solid tumors resistant to immune checkpoint inhibitors
- IBI3010: A FRα targeting biparatopic antibody-drug conjugate showing superior results compared to existing treatments
- IBI3014: A TROP2xPD-L1 bi-specific ADC combining tumor killing with immune checkpoint blockade
- IBI3022: A bi-specific ADC targeting Trop2 and B7H4 for gynecologic cancers
- IBI3026: A first-in-class anti-PD-1/IL-12 fusion protein for immunotherapy-resistant tumors
- IBI3019: A novel tri-specific antibody targeting EGFR/CDH17/CD16A for colorectal cancer
These developments demonstrate Innovent's advancing global R&D capabilities and commitment to creating innovative cancer treatments.
Innovent Biologics (HKEX: 01801) announces NMPA approval of limertinib for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. The approval is based on a Phase 3 trial of 337 patients comparing limertinib to gefitinib.
Key trial results show limertinib significantly improved median progression-free survival (PFS) to 20.7 months vs 9.7 months for gefitinib, representing a 56% risk reduction. In patients with CNS lesions, median CNS PFS was 20.7 months vs 7.1 months, showing a 72% risk reduction.
The drug demonstrated a well-tolerated safety profile with predominantly mild to moderate adverse events. This approval follows Innovent's commercial collaboration with ASK Pharm in 2024 for limertinib in Mainland China.